LifeMD Might Run Higher

2025-05-09 10:24:24 ET

Summary

• LifeMD grew its fiscal 2025 first quarter revenue by 48.8% over its year-ago comp.
• The company ended the first quarter with cash and cash equivalents of $34.4 million. Adjusted EBITDA was $8.7 million.
• Stagflation risks could spark some volatility but LFMD could see some valuation expansion if it hits guidance.

LifeMD ( LFMD ) is up 62% year-to-date, shaking off tariff concerns to shape what could be the early innings of a sustained comeback from 52-week lows. I'm bullish on the small-cap telehealth company, last covering the ticker with a buy rating in February. LFMD just reported fiscal 2025 first quarter earnings which saw dual beats, boosting the bullish case for the commons as the preferreds trade at near their $25 per share liquidation value after closing a more than double-digit discount from 2023. LFMD generated first quarter revenue of $65.69 million , up 48.8% over its year-ago comp and a beat by $3.23 million on consensus estimates. The pronounced ramp in revenue comes against a full year 2025 revenue guidance range of $268 million to $275 million, placing the company into a 1.36x multiple against the low end of the revenue range. ...

Read the full article on Seeking Alpha

For further details see: